Evidence map›Paper›PMID 37978452›Full record

ArticleBMC cancer2023

HPV testing in Polish population-based cervical cancer screening programme (HIPPO project)-study protocol of a randomised healthcare policy trial.

Patrycja Glinska, Katarzyna Komerska, Beata Janik, Julia Olkowicz, Ilona Jedrzejewska, Anna Macios, Paulina Wieszczy, Michal F Kaminski, Marc Arbyn, Andrzej Nowakowski

Registry-linked trialOpen access · goldAbstract readClinical Trial Protocol
In one paragraph

Article in BMC cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04111835 (HPV Testing In Polish POpulation-based Cervical Cancer Screening Program - a Randomized Healthcare Policy Trial), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04111835 nacompletednot on this map

HPV Testing In Polish POpulation-based Cervical Cancer Screening Program - a Randomized Healthcare Policy Trial

TypeinterventionalSponsorMaria Sklodowska-Curie National Research Institute of OncologyRan2019 to 2023Enrolled33,000ConditionsCervical CancerArmsOffering an alternative cervical cancer screening method - hrHPV molecular testing.
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 4 countries.

Patrycja GlinskaDepartment of Oncological Gastroenterology, Maria Sklodowska-Curie National Research Institute of Oncology, Roentgen Street 5, Warsaw, Poland. patrycja.glinska@nio.gov.pl.ORCID http://orcid.org/0000-0003-0165-7568
Katarzyna KomerskaDepartment of Cancer Prevention, Maria Sklodowska-Curie National Research Institute of Oncology, Roentgen Street 5, Warsaw, Poland.
Beata JanikDepartment of Cancer Prevention, Maria Sklodowska-Curie National Research Institute of Oncology, Roentgen Street 5, Warsaw, Poland.
Julia OlkowiczNational Institute of Geriatrics, Rheumatology and Rehabilitation, Spartanska Street 1, Warsaw, Poland.
Ilona JedrzejewskaDepartment of Cancer Prevention, Maria Sklodowska-Curie National Research Institute of Oncology, Roentgen Street 5, Warsaw, Poland.
Anna MaciosDepartment of Cancer Prevention, Maria Sklodowska-Curie National Research Institute of Oncology, Roentgen Street 5, Warsaw, Poland.
Paulina WieszczyDepartment of Gastroenterology, Hepatology and Clinical Oncology, Centre of Postgraduate Medical Education, Roentgen Street 5, Warsaw, Poland.
Michal F KaminskiDepartment of Oncological Gastroenterology, Maria Sklodowska-Curie National Research Institute of Oncology, Roentgen Street 5, Warsaw, Poland.
Marc ArbynUnit of Cancer Epidemiology, Belgian Cancer Centre, Sciensano, J. Wytsmanstreet 14, B1050, Brussels, Belgium.
Andrzej NowakowskiDepartment of Cancer Prevention, Maria Sklodowska-Curie National Research Institute of Oncology, Roentgen Street 5, Warsaw, Poland.ORCID http://orcid.org/0000-0002-5997-7516
The Maria Sklodowska-Curie National Research Institute of Oncology · PLUniversity of Oslo · NONational Institute of Geriatrics, Rheumatology and Rehabilitation · PLNational Institute of Oncology · HUPostgraduate School of Molecular Medicine · PLSciensano (Belgium) · BE

Funding

Ministry of Health of Poland "HPV-DNA pilot study"Ministry of Health of Poland The contract numbered - 1/2-3/1/2020/97/220
6 · The paper itself

Abstract

backgroundAn Organised Cervical Cancer Screening Programme (OCCSP) was started in Poland in 2006/2007. Each woman aged 25 to 59 is eligible for a free Pap test every 3 years in OCCSP. Despite implementation of the OCCSP, the age-standardised cervical cancer (CC) incidence and mortality rates in 2019 were 7.3/100 000 and 3.9/100 000 respectively and were still higher than those in Western European countries with well-organised screening programmes. Apart from low coverage of the OCCSP, suboptimal performance of the screening test (conventional cytology) may be partially responsible for this situation. Several countries have already incorporated high risk Human Papillomavirus (hrHPV) testing in CC screening as a more sensitive tool reducing the risk of missing precancerous lesions and allowing for extension of screening intervals. The European Guidelines for Quality Assurance in Cervical Cancer Screening recommend pilot evaluation of a new screening test in country-specific conditions before its implementation.

methodsThe HIPPO project (HPV testing In Polish POpulation-based cervical cancer screening program) is a randomised health services study nested in the OCCSP in Poland. The project will randomise 33 000 women aged 30-59 years to cytology or hrHPV testing (ratio: 1:1) with age stratification. In the cytology arm women with repeated Atypical Squamous Cells of Undetermined Significance (ASC-US) or ≥ Low-Grade Squamous Intraepithelial Lesions (LSIL) are referred for colposcopy. In the other arm, hrHPV ( +) women with ≥ ASC-US reflex Liquid-Based Cytology (LBC) are referred for colposcopy. Primary endpoints include detection rates of histologically confirmed high grade intraepithelial lesions or worse (CIN2 +) in each arm. DISCUSSION: This pilot randomised healthcare study nested in the OCCSP in Poland will assess and compare the performance of hrHPV testing to current standard-cytology in order to make decisions on implementation of HPV-based screening in the country.

trial registrationThis randomised healthcare service study was prospectively registered at https://clinicaltrials.gov/ (identifier: NCT04111835, protocol ID 28/2019) on 19th of September 2019.

Indexed as

Atypical Squamous Cells of the CervixPapillomavirus InfectionsUterine Cervical DysplasiaUterine Cervical NeoplasmsColposcopyEarly Detection of CancerFemaleHealth PolicyHumansMass ScreeningPapillomaviridaePolandPregnancyRandomized Controlled Trials as TopicVaginal SmearsCervical cancerCytologyhrHPV testPolandScreening programme

Identifiers

PMID37978452
PMCPMC10655392
OpenAlexW4388771661

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.